About OnyvaxSciencePress ReleasesClinical TrialsCareersContact
Onyvax - oncology vaccines 

Media Coverage

Current Press Releases

Archived Press Releases

Press Releases image

Archived Press Releases

March 24, 1999

DTI LINK Grant - New Generation Cancer Vaccines

March 24, 1999. Onyvax Limited (London, UK;http://www.onyvax.com) has received a grant of up to £313,000 awarded under the Cell Engineering LINK Programme by the Department of Trade & Industry. The DTI grant will help to support a three year collaborative programme at St George's Hospital Medical School under the direction of Angus Dalgleish, Professor of Clinical Oncology, for the development of second generation cancer vaccines.

Onyvax is a private company focussed on the development of therapies that harness the power of the immune system in the fight against cancer. It is believed that such an approach will benefit from the power and selectivity of the immune system whilst offering an excellent side-ef fect profile. To this end, Onyvax is developing vaccines targeted to specific cancers. The first, for prostate cancer, is currently being evaluated at St. George's Hospital in a phase I/II clinical study being conducted by the Urology Research Group.

Under the new collaborative research programme supported by the DTI, Onyvax and SGHMS will conduct research into generation prostate cancer vaccines, broadening and deepening the scope of the research programmes already in place in both parties' laboratories. Onyvax has negotiated an exclusive licence to all of the intellectual property generated by the project.

Anthony Walker, Chief Executive said: "We are delighted with the award of the LINK grant and the recognition by the DTI of the promise of our vaccine technology. The team at SGHMS is amongst the foremost engaged in the field of tumour immunology and the added resources being brought to bear will accelerate the development of safe and effective new treatments for cancer."

Back to Archived Releases Back to Archived Releases

© 1998-2009 Onyvax Ltd. All Rights Reserved